Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024697 | 0.91 | HRH3 (0.43) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL11955565 | 0.82 | HRH3 (0.47) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL5025697 | 0.81 | KMT2A (0.47) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL5023073 | 0.80 | KMT2A (0.49) | HRH3CYP1A2CYP2D6KDM4EKMT2A | |
| SCHEMBL6865800 | 0.80 | KDM4E (0.41) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL487617 | 0.79 | HRH3 (0.55) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL30398570 | 0.79 | HRH3 (0.55) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL5024694 | 0.79 | KDM4E (0.42) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL5024698 | 0.79 | KDM4E (0.42) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 | |
| SCHEMBL15483889 | 0.79 | HRH3 (0.39) | HRH3CYP1A2CYP2D6KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3619196-B1 | 2-{[2-(PHENYLOXYMETHYL)PYRIDIN-5-YL]OXY}-ETHANAMIN-DERIVATIVES AND RELATED COMPOUNDS AS PESTICIDES E.G. FOR CROP PROTECTION | BAYER CROPSCIENCE AG (DE) | 2022-03-30 | — | — | EP | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | HRH3 3203/4885CYP1A2 3391/4885CYP2D6 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.